|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
PAR2 mediated tryptase-induced cell migration and might contribute to the invasion of cancer cells at the edge of tumor.
|
31598400 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
All tumors were associated with normal or low serum alpha fetoprotein levels, and showed an absence of immunohistochemical staining of hepatocellular markers (Hep-par1, Arginase) and loss of INI1 staining.
|
31835848 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These features, among others, make PRR-targeting therapies an attractive strategy in immuno-oncology.
|
31123052 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Blood and tumor biopsy samples were collected pre- and on-treatment in the expansion cohort for PAR levels and proteomic endpoints.
|
31080557 |
2019 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Secondary endpoints included efficacy, characterization of PAR levels using ELISA, DDR alterations with targeted next generation sequencing and transcriptome analysis, tumor mutation burden (TMB) and microsatellite instability (MSI) status.
|
30635165 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Western blot was performed to determine protein expression.<b>Results:</b> The expression of <i>PAR-2</i> mRNA was up-regulated in OSCC tissue and cells (<i>P</i><0.01), and its mRNA level was obviously correlated to tumor differentiation and TNM stage in OSCC (<i>P</i><0.05 for both).
|
31213575 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Using a model of subcutaneous implantation of MDA-MB-231 cells in nude mice, PAR1-PR enhanced tumour growth more markedly than PAR4-PR, and seemed to achieve the exaggeration by promoting more profound tumour angiogenesis.
|
28697175 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
PAR-1 is expressed not only in epithelium, neurons, astrocytes, immune cells, but also in cancer-associated fibroblasts, ECs (epithelial cells), myocytes of blood vessels, mast cells, and macrophages in tumor microenvironment, whereas PAR-1 stimulates macrophages to synthesize and secrete thrombin as well as other growth factors, resulting in enhanced cell proliferation, tumor growth and metastasis.
|
29291033 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Overall, our data provide evidence that PAR-1 in NSCLC is mainly expressed on cells that constitute the pulmonary tumor microenvironment, including vascular endothelial cells, macrophages and stromal fibroblasts.
|
28173772 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The roles of PXR on cancer cell proliferation, apoptosis and tumor growth with L-OHP-treated were investigated by MTS, colony formation, flow cytometry and xenograft tumor assays.
|
28356150 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In this study, we aimed to explore if dabigatran may affect mechanisms favoring tumor growth by interfering with thrombin-induced PAR-1 activation.
|
27600331 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
PRMT1 may be an important co-activator of PXR in activating MDR1 gene during acquired resistance, and PRMT1 inhibitor combined with chemotherapy drugs may be a new strategy for overcoming tumor MDR.
|
26934120 |
2016 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Among the 3 genes, PRR(L) form of NUMB gene is highly expressed in TT and positively correlated with tumor size, while PRR(S) is lacking in TT and negatively correlated with NOTCH expression suggesting that PRR(S) might be protective in tumorogenesis and shows NOTCH pathway down regulation ability.
|
26261495 |
2015 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
F3/TF and F2R/PAR-1 mRNA expression are upregulated in SHH tumors and correlate with higher levels of hepatocyte growth factor receptor (MET).
|
25163932 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In the present study, male transgenic mice expressing human CAR and PXR were used to detect possible differences between wild-type (WT) and humanized mice in their response to CAR activation in a tumor initiation/promotion experiment with a single injection of the tumor initiator N-nitrosodiethylamine preceding chronic PB treatment for 10 months.
|
24863967 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In parallel, when a truncated PAR2 was utilized in a xenograft mouse model, it inhibited PAR1-PAR2-driven tumor growth in vivo.
|
24177339 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
PAR-1 enhances monocyte recruitment into the tumor microenvironment by regulating monocyte migration and fibroblast dependent chemokine production thereby inducing chemoresistance.
|
24436106 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The inhibitory effects of specific PAR1 antagonists in live animals have also indicated that the mechanisms of MMP-1-dependent vascular permeability in tumors involve endothelial PAR1 activation.
|
23687338 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
PAR-1 mediates angiogenesis and impacts the process of tumor growth and disease progression.
|
23517743 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Overall, our results enlighten the mechanism by which tissue factor promotes tumor growth through PAR1, and they show how EPCR can attenuate the growth of tissue factor-expressing tumor cells.
|
23539451 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The tumor suppressor TERE1 (UBIAD1) prenyltransferase regulates the elevated cholesterol phenotype in castration resistant prostate cancer by controlling a program of ligand dependent SXR target genes.
|
23919967 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
By deregulating protease activated receptors (PAR1/2) oncogenes may also change tumour cell responses to coagulation factor signalling.
|
22682129 |
2012 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In turn, the thrombin receptor, PAR-1, regulates the expression of the gap junction protein Connexin-43 and the tumor suppressor gene Maspin.
|
21147226 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Pregnane X receptor suppressed significantly HT29 xenograft tumour growth in nude mice compared with control (310+/-6.2 vs 120+/-6 mg, P<0.01).
|
20531417 |
2010 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Our data suggest PAR1 overexpression may be involved in the development of metastases in breast cancer patient and is associated with undifferentiated cellular progression of the tumor.
|
19538737 |
2009 |